Scarica l'app Stockscreener
4.41
2.22%
-0.10
Dopo l'orario di chiusura:
4.42
0.010
+0.23%
Nuvation Bio Inc Borsa (NUVB) Ultime notizie
2026-04-05 | Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NYSE:NUVB | Press Release - Stockhouse
Nuvation Bio Inc. (NUVB): Billionaire David Abrams has a long-term bet on this stock - MSN
Aug Reactions: Is Nuvation Bio Inc exposed to currency risks2026 Price Momentum & Daily Profit Focused Stock Screening - baoquankhu1.vn
Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity? - Sahm
Bullish analyst sentiment on Nuvation Bio (NUVB) amid early commercialization progress - MSN
2026-04-03 | Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc. (NUVB) Shareholders to Inquire about Securities Investigation | NYSE:NUVB | Press Release - Stockhouse
Nuvation Bio Inc. (NUVB) amends protocol on safusidenib trials in astrocytoma - MSN
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact L - GuruFocus
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Nuvation Bio gains global rights to brain cancer therapy from Daiichi Sankyo - MSN
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nuvation Bio Inc. (NUVB) And Encourages Investors to Connect - ACCESS Newswire
Nuvation Bio (NYSE:NUVB) Earns "Outperform" Rating from Wedbush - MarketBeat
NUVB Stock Price, Quote & Chart | NUVATION BIO INC (NYSE:NUVB) - ChartMill
Nuvation Bio secures global rights to safusidenib from Daiichi Sankyo By Investing.com - au.investing.com
Truist reiterates Buy on Nuvation Bio stock, $12 target on Japan deal - au.investing.com
Nuvation Bio announces acquisition of Japan rights to safusidenib from Daiichi Sankyo - MarketScreener
Nuvation Bio Announces Acquisition Of Japan Rights To Safusidenib From Daiichi Sankyo - TradingView
Nuvation gains global rights to brain cancer drug (NUVB:NYSE) - seekingalpha.com
Nuvation Bio secures global rights to safusidenib from Daiichi Sankyo - Investing.com
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo - PR Newswire
Nuvation Bio Inc. (NUVB) and Eisai Get EMA Validation for Taletrectinib - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc. (NUVB) Stockholders to Inquire about Securities Investigation - accessnewswire.com
5 Best Stocks Under $10 to Buy and Hold Forever - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nuvation Bio Inc. (NUVB) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
A Look At Nuvation Bio’s Valuation As EMA Validates Taletrectinib Application In Europe - Sahm
Nuvation Bio, Eisai application for taletrectinib for NSCLC accepted by EMA - MSN
Eisai And Nuvation Bio Advance Taletrectinib With EMA Validation For ROS1 Positive Lung Cancer - BioPharma APAC
Profit Review: Can Nuvation Bio Inc sustain earnings growth2026 Institutional & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Nuvation Bio outlines first-line IBTROZI growth strategy with 50-month median DOR amid expanding global partnerships - MSN
H.C. Wainwright reiterates Nuvation Bio stock rating on EU filing By Investing.com - Investing.com India
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Wedbush Reiterates Outperform Rating for Nuvation Bio (NYSE:NUVB) - MarketBeat
H.C. Wainwright reiterates Nuvation Bio stock rating on EU filing - Investing.com
H.C. Wainwright Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $17 - Moomoo
March 2026's Promising Penny Stocks To Watch - simplywall.st
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency - JCN Newswire
Nuvation Bio Inc. (NUVB): Billionaire David Abrams Has a Long-Term Bet on This Stock - Yahoo Finance
12 Best Stocks to Buy According to Billionaire David Abrams - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc.NUVB - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc. (NUVB) Investors to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio ... - caledonianrecord.com
2026-03-24 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nuvation Bio Inc. (NUVB) And Encourages Investors to Reach Out | NYSE:NUVB | Press Release - Stockhouse
Nuvation Bio (NUVB)’s Taletrectinib Selected as Preferred Agent for Cancer Treatment - MSN
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm - weeklyvoice.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):